Oncology Nursing News®

Register now to learn about a new option for relapsed or refractory follicular lymphoma

Lung Cancer

FDA Approves Guardant360 CDx Liquid Biopsy for Genomic Profiling for Solid Cancers

FDA Approves Guardant360 CDx Liquid Biopsy for Genomic Profiling for Solid Cancers

BY KRISTI ROSA

Immunotherapy-Related Pneumonitis in Lung Cancer

Immunotherapy-Related Pneumonitis in Lung Cancer

BY BETH SANDY, MSN, CRNP

Lung Cancer Treatment Continues to Improve

Lung Cancer Treatment Continues to Improve

BY CAROLINE SEYMOUR

NCCN Recommends Lurbinectedin for Second-Line Treatment of Relapsed SCLC

NCCN Recommends Lurbinectedin for Second-Line Treatment of Relapsed SCLC

BY JESSICA HERGERT

Mental Health Treatment May Improve Cancer Outcomes

Mental Health Treatment May Improve Cancer Outcomes

BY BRIELLE BENYON

2020 Brings Exciting Advancements for NSCLC Treatment

2020 Brings Exciting Advancements for NSCLC Treatment

BY CAROLINE SEYMOUR

Immunotherapy/Chemotherapy Regimen Improves Lung Cancer Outcomes, Regardless of Biomarker Status

Immunotherapy/Chemotherapy Regimen Improves Lung Cancer Outcomes, Regardless of Biomarker Status

BY GINA COLUMBUS

FDA Approves Pembrolizumab for TMB-High Solid Tumors

FDA Approves Pembrolizumab for TMB-High Solid Tumors

FDA Approves Lurbinectedin for Metastatic Small Cell Lung Cancer

FDA Approves Lurbinectedin for Metastatic Small Cell Lung Cancer

BY BY ONN STAFF

Upfront 4-Drug Regimen Is Tolerable in Lung Cancer Treatment

Upfront 4-Drug Regimen Is Tolerable in Lung Cancer Treatment

BY BRITTANY COTE

External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc

OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives

About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.